CUGBP1 Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

CUGBP1 Polyklonal Antikörper für WB, IHC, IF/ICC, IP, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, IHC, IF/ICC, IP, ELISA

Konjugation

Unkonjugiert

Publikationen

4

Kat-Nr. : 13002-1-AP

Synonyme

CELF1, CELF 1, Bruno-like protein 2, BRUNOL2, Bruno like protein 2

---

Galerie der Validierungsdaten

• 

  WB analysis using 13002-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 13002-1-AP (CUGBP1 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HT-1080 using 13002-1-AP

  HT-1080 cells were subjected to SDS PAGE followed by western blot with 13002-1-AP (CUGBP1 antibody) at dilution of 1:200 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HL-60 using 13002-1-AP

  HL-60 cells were subjected to SDS PAGE followed by western blot with 13002-1-AP (CUGBP1 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of NIH/3T3 using 13002-1-AP

  NIH/3T3 cells were subjected to SDS PAGE followed by western blot with 13002-1-AP (CUGBP1 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 13002-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 13002-1-AP (CUGBP1 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  IP experiment of HeLa using 13002-1-AP

  IP result of anti-CUGBP1 (IP:13002-1-AP, 4ug; Detection:13002-1-AP 1:500) with HeLa cells lysate 3200ug.

• 

  IHC staining of human breast cancer using 13002-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 13002-1-AP (CUGBP1 antibody) at dilution of 1:200 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 13002-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 13002-1-AP (CUGBP1 antibody) at dilution of 1:200 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human testis using 13002-1-AP

  Immunohistochemical analysis of paraffin-embedded human testis tissue slide using 13002-1-AP (CUGBP1 Antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human testis using 13002-1-AP

  Immunohistochemical analysis of paraffin-embedded human testis tissue slide using 13002-1-AP (CUGBP1 Antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human skin cancer using 13002-1-AP

  Immunohistochemical analysis of paraffin-embedded human skin cancer tissue slide using 13002-1-AP (CUGBP1 Antibody) at dilution of 1:50.

• 

  IHC staining of human skin cancer using 13002-1-AP

  Immunohistochemical analysis of paraffin-embedded human skin cancer tissue slide using 13002-1-AP (CUGBP1 Antibody) at dilution of 1:50.

• 

  IF Staining of HeLa using 13002-1-AP

  Immunofluorescent analysis of Hela cells, using CUGBP1 antibody 13002-1-AP at 1:50 dilution and FITC-labeled donkey anti-rabbit IgG (green). Blue pseudocolor = DAPI (fluorescent DNA dye).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HL-60-Zellen, HeLa-Zellen, HT-1080.Zellen, Maushirngewebe, NIH/3T3-Zellen, Rattenhirngewebe
• Erfolgreiche IP: HeLa-Zellen
• Erfolgreiche Detektion in IHC: humanes Mammakarzinomgewebe, humanes Hautkrebsgewebe, humanes Hodengewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.
• Erfolgreiche Detektion in IF/ICC: HeLa-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:4000
• Immunpräzipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunhistochemie (IHC): IHC : 1:50-1:500
• Immunfluoreszenz (IF)/ICC: IF/ICC : 1:20-1:200

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• KD/KO: See 2 publications below
• WB: See 3 publications below
• IHC: See 1 publications below

Produktinformation

13002-1-AP bindet in WB, IHC, IF/ICC, IP, ELISA CUGBP1 und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• In Publikationen genannte Reaktivität: human, Maus
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: CUGBP1 fusion protein Ag3677
• Vollständiger Name: CUG triplet repeat, RNA binding protein 1
• Berechnetes Molekulargewicht: 483 aa, 52 kDa
• Beobachtetes Molekulargewicht: 51-55 kDa
• GenBank-Zugangsnummer: BC031079
• Gene symbol: CUGBP1
• Gene ID (NCBI): 10658
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

CUG triplet repeat RNA binding protein 1 (CUGBP1) is a member of the CUGBP Elav-like family (CELF), which plays an important role in cardiac development and function (PMID: 17130239). CUGBP1 has also been shown to localize to cytoplasmic stress granules when cells are stressed.

Publikationen

Species	Application	Title
mouse	IHC	Hum Mol Genet; CGG repeats in RNA modulate expression of TDP-43 in mouse and fly models of fragile X tremor ataxia syndrome.; Authors - Jocelyn N Galloway
human	WB	Carcinogenesis; RNA-binding protein CUGBP1 controls the differential INSR splicing in molecular subtypes of breast cancer cells and affects cell aggressiveness.; Authors - Gena Huang ; KD Validated
human	WB	Sci Rep; DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis.; Authors - Xu Zhao ; KD Validated
human,mouse	WB	Bioengineered; Guizhi Fuling pill attenuates liver fibrosis in vitro and in vivo via inhibiting TGF-β1/Smad2/3 and activating IFN-γ/Smad7 signaling pathways.; Authors - Zhongliang Liu